Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Curis Inc (NASDAQ:CRIS)

3.18
Delayed Data
As of 1:49pm ET
 -0.02 / -0.63%
Today’s Change
1.09
Today|||52-Week Range
3.75
+112.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$410.7M

Company Description

Curis, Inc. is a biotechnology company, which is to develop and commercialize innovative drug candidates for the treatment of human cancers. Its pipeline includes two clinical stage drug candidates: CUDC-907, a dual HDAC and PI3K inhibitor, and CUDC-427, a small molecule IAP antagonist. The company conducts research programs both internally and through strategic collaborations. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Contact Information

Curis, Inc.
4 Maguire Road
Lexington Massachusetts 02421
P:(617) 503-6500
Investor Relations:
(617) 503-6605

Employees

Shareholders

Other institutional26.95%
Mutual fund holders23.56%
Individual stakeholders19.96%

Top Executives

Ali FattaeyPresident, Chief Executive Officer & Director
Michael P. GraySecretary, Chief Financial & Business Officer
Jaye VinerChief Medical Officer & Executive Vice President
Tania ChanderVice President-Product Development
Mani MohindruVP-Corporate Strategy & Investor Relations